ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alnylam Pharmaceuticals Inc (ALNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as strong revenue growth and a promising product pipeline, the company's declining profitability metrics and mixed analyst sentiment suggest caution. The technical indicators and options data do not strongly support an immediate entry point.
The MACD is positive and expanding, suggesting bullish momentum. However, RSI is neutral at 50.134, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a lack of strong upward trend. Key resistance levels are at R1: 342.412 and R2: 353.715, while support levels are at S1: 305.82 and S2: 294.517.
Revenue increased by 84.95% YoY in Q4 2025, showing strong top-line growth.
The Amvuttra launch in TTR is performing well, with significant market opportunity due to undiagnosed patients.
Analysts see long-term upside potential, with price targets ranging up to $
Diversification into treatments for Huntington's disease, obesity, and HHT could drive future growth.
Net income dropped by -322.56% YoY, and EPS declined by -310.77% YoY in Q4 2025, reflecting poor profitability.
Gross margin decreased by 8.55% YoY, indicating cost pressures.
Mixed analyst sentiment with some firms lowering price targets and highlighting near-term headwinds.
No significant hedge fund or insider trading activity to indicate strong institutional confidence.
In Q4 2025, revenue grew by 84.95% YoY to $1.097 billion, but net income dropped significantly by -322.56% YoY to $186.4 million. EPS also fell by -310.77% YoY to $1.37, and gross margin declined to 75.6%, down 8.55% YoY. While revenue growth is strong, declining profitability metrics are a concern.
Analysts maintain a generally positive outlook with several Buy ratings and price targets ranging from $360 to $510. However, recent target reductions and concerns about near-term headwinds suggest mixed sentiment. Some analysts believe the stock is undervalued and see long-term potential, while others highlight challenges in Q1 2026.
